TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: All-cause dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Peak exercise efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in starting post-operative radiation treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relieving the Discomfort of Dry Mouth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Slope of the regression line of 1/SCr versus time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in bacterial translocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline labor Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour mean renal threshold for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Surfactant administration vs mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentages of immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difficulties in Emotion Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impulsiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Noninferiority margin of extended interval dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Numeric Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Brief Pain inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms consistent with COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative patency of internal jugular vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: All noises from THA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nonmedical prescription stimulant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerable Dose (MTD) of Bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC Survival (Life Span) in Days of Transfused Autologous RBCs
Endpoint domain: Mortality/survival
Primary endpoint: RBC Survival (Life Span) in Days of Transfused Allogeneic RBCs
Endpoint domain: Mortality/survival
Primary endpoint: Change in hippocampal connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients Achieving ASAS 40 Improvement Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure Rate of Non-healing Wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Continuous Glucose Monitoring System Standard Deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: colorectal cancer screening utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Language and cognitive skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Osteoarthritis (OA) of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effects on the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse rate and blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived understanding of genomic testing results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived confidence explaining genomic testing results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of Reoffending
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Placebo-corrected change-from-baseline QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Post-thrombotic Syndrome (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incremental area under the curve (iAUC) (Glucose tolerance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental area under the curve (iAUC) (insulin sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Working memory capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Screen-Detected Breast Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in trans-middle ear N2O exchange constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With Clinical Remission (CDAI<150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of E7046
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of E7046
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nipple pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Post-absorptive Lipid Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hair retention scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Related Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Free Survival in Resected High Risk Patients Treated With Adjuvant Pembrolizumab and Chemoradiation
Endpoint domain: Mortality/survival
Primary endpoint: Disease Free Survival in Resected Intermediate Risk Patients Treated With Adjuvant Pembrolizumab and Radiation
Endpoint domain: Mortality/survival
Primary endpoint: Self-report pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak change from baseline of urinary Neutrophil gelatinase-associated lipocalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Feasibility of using helical tomotherapy to deliver IMRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hepatic blood flow difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Net whole-body protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of meningococcal rSBA responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Health literacy as assessed by Literacy Assessment in Diabetes (LAD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Health literacy as assessed by the Newest Vital Sign
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Margin of Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symbol Digit Modality Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Brain structural connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of FNA-Ctn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CREB phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolomics profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a ≥ 2-grade Improvement on the Facial Wrinkle Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: At least 75% Reduction in Eczema Area and Severity Index (EASI75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of PrEP drug in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to weaning from oxygen supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 3-months PostConcussion-Like Syndrome (PCLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular and Humoral Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Composite Endpoint of Death, Graft Loss, or eGFR < 45ml/Min
Endpoint domain: Mortality/survival
Primary endpoint: Change in Spine Bone Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD characteristics assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preliminary efficacy data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed-Up & Go Test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client Satisfaction Questionnaire (CSQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cornell Services Index (CSI)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of subjects without virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent below 4 mmol/L capillary blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of Pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of SBRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight bias internalization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants who Achieved Hb ≥110 g/L in the First 20 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants who Achieved Mean Hb ≥100 g/L Averaged Over Weeks 17 to 21 Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Hb Value Averaged Over Weeks 33 to 37 Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression Free Survival at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of PFC
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from DL infection events
Endpoint domain: Adverse events/effects
Primary endpoint: safety assessed by absence of related events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sentence Recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary concentration of cortisol and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in the volume of enhancing synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: vascular compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean change in the symptom identified by the patient to be most bothersome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in maturation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knowledge of key safety issues pertaining to ticagrelor
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Disease Free Survival at One Year
Endpoint domain: Mortality/survival
Primary endpoint: LDL-C at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of sedation and analgesia in ventilated neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year event free survival
Endpoint domain: Mortality/survival
Primary endpoint: PK parameters (Cmax, Tmax, AUC0-8h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Maximum Administered Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Anidulafungin area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anidulafungin half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anidulafungin maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anidulafungin elimination fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Total Functional Movement Screen (FMS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Movement Efficiency (ME) Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dynamic Balance Ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV Type Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Standardized uptake value (SUV) on PET scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Cutaneous Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of venous reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum tolerated dose defined by dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in total cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Low Density Lipoprotein (LDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in fasting glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in fasting insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Diurnal Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Occurrence of Factor IX (FIX) Inhibitor Development
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in BMI after 6 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Dementia Rating (CDR)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in serum level of study biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of ruptured or eroded plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Episodic memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvements in first and second phase insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Occurrence of a cardiac event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with HIV plasma RNA <50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence Abstinence Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Control at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adherence of Use of Patient Asthma Inhalers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients Without GVHD at 100 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Influenza-specific immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: gingival cervicular fluid BMP-2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Acceptable Diet Scores (MAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimum diet diversity (MDD-W)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cardiac mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Probing depth (PPD) at test tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sub-basal corneal nerve density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sub-basal corneal nerve tortuosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in mitochondrial respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External chest wall measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient's perception of deformity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global Rating of Change Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area Under the Curve (AUC) of RSV Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in cerebral regional oxygen saturation (crSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in Global Aesthetic Improvement Scale (GAIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline serum Creatinine at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline urine microalbuminuria at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in patient-reported outcome measures (PROM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in chewing efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the amplitude of P300
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the Latency of P300
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy measured by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radioiodine uptake and clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Age-adjusted MAC of sevoflurane per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep and performance of firefighters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline In Plasma Intact C3 Level On Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knee osteoarthritis outcome scores (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adjusted Mean Change in Endogenous Thrombin Potential (ETP) From Day 4 Pre-Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adjusted Mean Change in Endogenous Thrombin Potential (ETP) From Day 1 Pre-Dose Apixaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety outcome
Endpoint domain: Adverse events/effects